GE HealthCare Technologies Inc. (GEHC) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of GE HealthCare Technologies Inc. stock $69.92, price $83.75, that is 16.5% below the price, quality 58 out of 100. Rating: overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
47‑month range $55.67 – $93.51 · fair‑value band $41.88 – $101.56 · the $83.75 price screens above the $69.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow GE HealthCare Technologies in your weekly email
Every Wednesday you see whether GE HealthCare Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally.
Show moreShow less
The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products.
The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products.
The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products.
The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries.
The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes.
The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Stock analysis
GE HealthCare Technologies Inc. (GEHC) currently trades at $83.75, while our model-based Fair Value estimate is $69.92, 17% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $91.28 per share, and 4 of the 23 models we run sit above the $83.75 price.
Bear case: the Economic Profit group reads lowest at $35.03, and 19 of the 23 models stay below the price. Data coverage for this calculation is high.
Scenario range: $41.88 (bear) to $101.56 (bull), the price of $83.75 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
GE HealthCare Technologies Inc. reported revenue of $20.6B in FY2025 versus $17.6B in FY2021, a compound +4.1%/yr. Reported net income was $2.1B in FY2025, compounding −1.9%/yr from FY2021.
Key figures
Market cap $38.0B Large · P/E ratio 17.7 · P/S ratio 1.76 · EPS (TTM) $4.73 · Dividend yield 0.2% · Net margin 10.0% · Return on equity 20.0% · Return on assets (EBIT) 8.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 61 out of 100 (medium confidence).
What moves the price
The share trades about 5% below its 52-week high and 41% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −17%, GEHC screens richer than that median.
Fair Value models
Bear$41.88Fair Value $69.92Bull$101.56
Price $83.75 · Downside -16.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($3.89 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 3 officers or directors bought shares worth $805,175, most recently on May 22, 2026. Buying cluster
BuyKevin LoboDirector10,000 shares at $64.18$641,800May 22, 2026
BuyRodney F HochmanDirector1,618 shares at $62.03$100,365May 12, 2026
BuyWatkin Phoebe L. YangDirector1,000 shares at $63.01$63,010May 8, 2026
BuyH Lawrence Culp JrDirector80,805 shares at $61.88$5.0MMay 6, 2026
BuyWilliam J StrombergDirector1,000 shares at $61.69$61,690May 6, 2026
BuyJames SaccaroChief Financial Officer3,310 shares at $60.60$200,586May 1, 2026
BuyPeter J ArduiniPresident and CEO, Director4,169 shares at $59.93$249,848Apr 30, 2026
BuyFrank R JimenezGC & Corporate Secretary1,750 shares at $60.45$105,788Apr 30, 2026
Plus 25 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.66/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+2.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.9%
Dividend (yield on the price)0.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 13%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +11.4% a year for the price and +2.2% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Decent ROE and margins stand out as the main strength while limited evidence of a durable moat as a new standalone entity with debt near equity remains the chief weakness.
Main risk: Competitors like Curium after acquiring Lantheus and Siemens Healthineers via PETNET could maintain superior U.S. networks for PET radiopharmaceuticals, limiting GE HealthCare's supply access or share in high-growth tracers and squeezing margins.
Bull case: By integrating SOFIE's network with its imaging systems and tracers like FAPI-74, GE HealthCare could secure supply, accelerate launches in oncology and cardiology and gain an edge over rivals in the PET radiopharmaceutical market.
Bear case: If integration of SOFIE proves challenging or rivals expand networks faster, GE HealthCare might face supply limitations, slower growth in pharmaceutical diagnostics and margin pressure from competitors controlling more final-mile delivery.
GE HealthCare is acquiring SOFIE Biosciences to establish its own US manufacturing network for PET radiopharmaceuticals. The move strengthens the pharmaceutical diagnostics segment by securing supply for its imaging agents and gaining rights to a late-stage cancer tracer. Will the benefits of tighter control over this high-growth area exceed the challenges of integrating a contract manufacturer?
Compare GE HealthCare Technologies Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 321 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−16.5% · Above median
Profitability
Return on equity (12 months)20.0% · Top 25%
Return on assets5.7% · Above median
Net margin (12 months)10.0% · Above median
Operating margin (12 months)15.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)7.2% · Above median
Dividend yield (12 months)0.2% · Bottom 25%
Balance sheet
Debt / equity0.92× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)17.7× · Cheaper than median
P/B3.66× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)1.76× · Cheaper than median
Price / free cash flow (fiscal year)25.3× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "GE HealthCare Technologies Inc. Fair Value". https://www.fairvalue-calculator.com/stock/GEHC
Frequently asked questions
Is GE HealthCare Technologies Inc. (GEHC) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $69.92 versus a price of $83.75, about 17% lower (overvalued).
What is the fair value of GEHC?
Our model-based fair value for GE HealthCare Technologies Inc. is $69.92 (as of Nov 5, 2026), built from audited fundamentals. The current price: $83.75.
What is the quality score of GEHC?
GE HealthCare Technologies Inc. has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GE HealthCare Technologies Inc. (GEHC)?
Our model-based price target is the fair value of $69.92 (as of Nov 5, 2026) from 23 valuation models. Cautious scenario $41.88, optimistic scenario $101.56. It is a calculation from audited fundamentals, not an analyst target.
What is the GE HealthCare Technologies Inc. stock forecast for 2026?
Our models put fair value at $69.92, about 17% lower versus a price of $83.75 (overvalued). Cautious scenario $41.88, optimistic scenario $101.56. The calculation is refreshed regularly with new filings.
What is the revenue of GE HealthCare Technologies Inc. (GEHC)?
GE HealthCare Technologies Inc. reported trailing-twelve-month revenue of about $21.6B (latest available figure, as of Nov 5, 2026).
Does GE HealthCare Technologies Inc. pay a dividend?
GE HealthCare Technologies Inc. currently shows a dividend yield of 0.17% relative to its recent price (as of Nov 5, 2026).
What growth is priced into GE HealthCare Technologies Inc. (GEHC)?
For today's price to be fair in a discounted-cash-flow model, GE HealthCare Technologies Inc. would have to grow free cash flow by +14.0 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.7 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of GEHC use?
Our models discount GE HealthCare Technologies Inc. at 8.9 %: a base by market capitalisation (large), damped by beta 0.85, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For GE HealthCare Technologies Inc. that is +14.0 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has GE HealthCare Technologies Inc. (GEHC) delivered so far?
Over the past 5 years revenue at GE HealthCare Technologies Inc. grew +3.7 % a year. The price currently implies +14.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of GE HealthCare Technologies Inc. (GEHC) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into GE HealthCare Technologies Inc. (+14.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of GE HealthCare Technologies Inc. (GEHC)?
The free-cash-flow yield on the price is 3.96 %: that much free cash flow GE HealthCare Technologies Inc. produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of GE HealthCare Technologies Inc. (GEHC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GE HealthCare Technologies Inc. it is $69.92 per share (as of Nov 5, 2026), against a price of $83.75. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is GE HealthCare Technologies Inc. stock overvalued or undervalued in 2026?
As of Nov 5, 2026, GEHC trades above its calculated fair value: price $83.75, fair value $69.92, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GEHC?
No. The price is what the market pays today ($83.75); the fair value is what the company's own numbers justify ($69.92). For GE HealthCare Technologies Inc. the two are $13.83 per share apart. That gap is exactly why we show both numbers side by side.
How much is GE HealthCare Technologies Inc. worth?
The market values GE HealthCare Technologies Inc. at about $38.0B (market capitalisation, as of Nov 5, 2026). Per share that is $83.75; our models calculate a fair value of $69.92 per share.
What do the bullish and bearish scenarios say about GEHC?
Our models span a range for GE HealthCare Technologies Inc.: cautious scenario $41.88, base $69.92, optimistic $101.56 per share (as of Nov 5, 2026, price $83.75). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GEHC?
GE HealthCare Technologies Inc. trades at a price-to-earnings ratio of 17.7 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $69.92 is built from several models across several years. Other multiples: PEG 1.9, P/B 3.7, P/S 1.8, EV/EBITDA 12.0.
What is the PEG ratio of GEHC?
The PEG ratio of GE HealthCare Technologies Inc. is 1.91 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of GE HealthCare Technologies Inc. (GEHC)?
Balance-sheet figures for GE HealthCare Technologies Inc. (as of Nov 5, 2026): return on equity 20.0%, debt of 0.92 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is GEHC from its 52-week high?
GE HealthCare Technologies Inc. trades at $83.75, about 5% below its 52-week high of $88.03 and 41% above the low of $59.45 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $69.92 is for.
Which stocks are comparable to GE HealthCare Technologies Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GE HealthCare Technologies Inc. stock attractive at the current price?
The data as of Nov 5, 2026: price $83.75, calculated fair value $69.92 (−17%), Quality Score 58/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GEHC calculated?
We run GE HealthCare Technologies Inc. through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $69.92, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. GE HealthCare Technologies Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GE HealthCare Technologies Inc. (GEHC)?
The closing price on Nov 5, 2026 was $83.75. Our model-based fair value is $69.92, about 17% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GE HealthCare Technologies Inc. right now?
Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($41.88 to $101.56) leaves room in how you read the outcome.
Key figures of GE HealthCare Technologies Inc.
How large is the market capitalisation of GE HealthCare Technologies Inc. (GEHC)?
The market capitalisation of GE HealthCare Technologies Inc. is $38.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GE HealthCare Technologies Inc. (GEHC)?
The price-to-sales ratio of GE HealthCare Technologies Inc. is 1.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GE HealthCare Technologies Inc. (GEHC)?
Earnings per share at GE HealthCare Technologies Inc. are $4.73 (price ÷ EPS = P/E 17.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of GE HealthCare Technologies Inc. (GEHC)?
The dividend yield of GE HealthCare Technologies Inc. is 0.2% (payout 3.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of GE HealthCare Technologies Inc. (GEHC)?
The net margin of GE HealthCare Technologies Inc. is 10.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GE HealthCare Technologies Inc. (GEHC)?
The return on equity (ROE) of GE HealthCare Technologies Inc. is 20.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GE HealthCare Technologies Inc. (GEHC)?
On an EBIT basis the return on assets of GE HealthCare Technologies Inc. is 8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GE HealthCare Technologies Inc. (GEHC)?
The operating margin of GE HealthCare Technologies Inc. is 15.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GE HealthCare Technologies Inc. (GEHC)?
Revenue at GE HealthCare Technologies Inc. is growing +7.2% versus a year earlier (3y avg +4.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at GE HealthCare Technologies Inc. (GEHC)?
Earnings per share at GE HealthCare Technologies Inc. are growing +39.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does GE HealthCare Technologies Inc. (GEHC) carry?
The net debt of GE HealthCare Technologies Inc. is $5.5B (fiscal year 2025, ≈ 3.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch GE HealthCare Technologies Inc. in the live analysis
One click puts GE HealthCare Technologies Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 5, 2026